Depomed to Present at the Stifel Healthcare Conference

NEWARK, Calif., Nov. 11, 2015 /PRNewswire/ -- Depomed, Inc. DEPO today announced that it will be presenting at the Stifel 2015 Healthcare Conference in New York City.  The presentation is scheduled for 3:45pm EST (12:45pm PST) Wednesday, November 18, 2015.

The presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com.  A recording of the webcast will be archived for 30 days on the company's website.

About Depomed 

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Our NUCYNTA® franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise, Nucynta ER and various partner product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com.  

NUCYNTA®, Gralise® CAMBIA®, Zipsor®, Lazanda® and Acuform® are registered trademarks of Depomed, Inc.

Investor Contact:

Depomed, Inc.

Christopher Keenan

510-744-8000

ckeenan@depomed.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/depomed-to-present-at-the-stifel-healthcare-conference-300177005.html

SOURCE Depomed, Inc.